Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study

Annals of Hematology

Volumn 72, Issue 4, 1996, Pages 216-222

  Thalhammer, F ^a   Geissler, K ^a   Jager U ^a   Kyrle, P A ^a   Pabinger, I ^a   Mitterbauer, M ^a   Gisslinger, H ^a   Knobl P ^a   Laczika, K ^a   Schneider, B ^a   Haas, O A ^b   Lechner, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Acute myeloid leukemia; Long term remission; Salvage chemotherapy

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CYTOGENETICS; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 15844378214     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050163     Document Type: Article

References (26)

1. Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone. etoposide and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210-1214
2. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide. mitoxantrone. and cytarabine-86 trial. J Clin Oncol 13:11-18
3. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84: 111a [Suppl]
4. Chopra R, Goldstone AH, McMillan AK, et al (1991) Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow. The British Autograft Group experience. J Clin Oncol 9:1840-1847
5. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA (1993) The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 83:404-411
6. Fenaux P, Le Deley MC, Castaigne S, et al (1993) Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82:3241-3249
7. Gale RP, Champlin RE (1986) Bone marrow transplantation in acute leukaemia. In: Gale RP. Hoffbrand AV (eds) Clinics in haematology. Saunders, London, pp 851-872
8. Gulati S, Acaba L, Yahalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpodien J, Andreeff M. Gee T (1992) Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant 10:129-134
9. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A (1995) Results of a randomised, double-blind placebo-controlled phaseIII study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukaemia. Blood 86:267a [Suppl]
10. Hiddemann W. Büchner T (1990) Treatment strategies in acute myeloid leukemia (AML). B. Second-line treatment. Blut 60:163-171
11. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744-749
12. Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WDC, Bartholomäus A. Bettelheim P, Becker K, Balleisen L, Lathan B, Koppler H, Grüneisen T, DonhuijsenAnt R, Reichle A, Heinecke A, Sauerland C, Buchner Th (1993) High-dose versus intermediate-dose cytosine arabino-side combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Leuk Lymphoma 10:133-137 [Suppl]
13. Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH (1984) High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphoblastic leukemia. J Clin Oncol 2:545
14. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6:232-238
15. Keating MJ, Kantarjian H, Smith TL, et al (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-1080
16. Meloni G, de Fabritiis P, Petti MC, Mandelli F (1990) BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 75:2282-2285
17. Petersen FB, Lynch MHE, Clift RA, Appelbaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P, Storb R, Rowley S, Sullivan KM, Witherspoon R, Weiden P, Thomas ED, Fisher L, Hansen JA, Buckner CD (1993) Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 11:1353-1360
18. Schiller G, Feig SA, Territo M, Wohlin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski J (1994) Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88:72-78
19. Schwartz RS, Mackintosh FR, Halpern J, Schrier SL, Greenberg PL (1984) Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia. Cancer 54:1672-1681
20. Selvaggi KJ, Wilson JW, Mills LE, Cornwall III GG, Hurd D, Dodge W, Gingrich R, Martin SE, McMillan R, Miller W, Ball ED (1994) Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow, Blood 83:1698-1705
21. Sierra J, Granena A, Garcia J, Vails A, Carreras E, Rovira M, Canals C, Martinez E, Punit C, Algara M, Marin P, Merino A, Terol MJ, Urbano-Ispizua A, Rozman C (1993) Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant 12:517-523
22. Spadea A, Petti MC, Fazi P, Vegna ML, Arcese W, Avvisati G, Spiriti MAA, Latagliata R, Meloni G, Testi AM, Amadori S. Mandelin F (1993) Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor-risk acute myeloid leukemia. Leukemia 7:549-552
23. Uhlman DL, Bloomfield CD, Hurd D. et al (1990) Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol 33:110-116
24. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA (1994) A phase-III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A South-eastern cancer study group trial. Leukemia 8:1847-1853
25. Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High-dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 29:142-146
26. Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate- and high-dose cytosine arabinoside in refractory acute leukemia. Onkologie 6:200-204